Back in April, a study conducted by the nonprofit Cochrane Group suggested that the $2 billion worth of Roche's ($RHHBY) Tamiflu and other flu fighters stockpiled by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback